{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["62(1)"],"submitter":["Dong X"],"funding":["Clinical and Experimental Research"],"pubmed_abstract":["<h4>Context</h4>Yi-Shen-Hua-Shi (YSHS) is a traditional Chinese medicine that treats chronic kidney disease (CKD). However, its efficacy in reducing proteinuria and underlying mechanisms is unknown.<h4>Objective</h4>This single-center randomized controlled trial explored whether YSHS could improve proteinuria and modulate the gut microbiota.<h4>Materials and methods</h4>120 CKD patients were enrolled and randomized to receive the renin-angiotensin-aldosterone system (RAAS) inhibitor plus YSHS (<i>n</i> = 56) or RAAS inhibitor (<i>n</i> = 47) alone for 4 months, and 103 patients completed the study. We collected baseline and follow-up fecal samples and clinical outcomes from participants. Total bacterial DNA was extracted, and the fecal microbiome was analyzed using bioinformatics.<h4>Resul"],"journal":["Pharmaceutical biology"],"pagination":["356-366"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11085992"],"repository":["biostudies-literature"],"pubmed_title":["Yi-Shen-Hua-Shi regulates intestinal microbiota dysbiosis and protects against proteinuria in patients with chronic kidney disease: a randomized controlled study."],"pmcid":["PMC11085992"],"pubmed_authors":["Li W","Li Y","Liu Z","Dong X","Zhang J","Fu W","Jia L","Zhang A"],"additional_accession":[]},"is_claimable":false,"name":"Yi-Shen-Hua-Shi regulates intestinal microbiota dysbiosis and protects against proteinuria in patients with chronic kidney disease: a randomized controlled study.","description":"<h4>Context</h4>Yi-Shen-Hua-Shi (YSHS) is a traditional Chinese medicine that treats chronic kidney disease (CKD). However, its efficacy in reducing proteinuria and underlying mechanisms is unknown.<h4>Objective</h4>This single-center randomized controlled trial explored whether YSHS could improve proteinuria and modulate the gut microbiota.<h4>Materials and methods</h4>120 CKD patients were enrolled and randomized to receive the renin-angiotensin-aldosterone system (RAAS) inhibitor plus YSHS (<i>n</i> = 56) or RAAS inhibitor (<i>n</i> = 47) alone for 4 months, and 103 patients completed the study. We collected baseline and follow-up fecal samples and clinical outcomes from participants. Total bacterial DNA was extracted, and the fecal microbiome was analyzed using bioinformatics.<h4>Resul","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-03T04:26:39.309Z","creation":"2026-04-24T03:09:38.372Z"},"accession":"S-EPMC11085992","cross_references":{"pubmed":["38720666"],"doi":["10.1080/13880209.2024.2345080"]}}